Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Caliway Biopharmaceuticals

Tracked across 1 events · 6 articles · First seen Sep 23, 2026 · Last active Sep 23, 2026

Sentiment
35
Attention
2
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 35
Tech
Caliway Biopharmaceuticals announced on September 21, 2026, final statistical results from its randomized, single-blind, placebo-controlled Phase 2 clinical trial CBL-0202DD evaluating CBL-514 for the treatment of Dercum's Disease, a rare disorder characterized by painful lipomas.…
Impact: Caliway Biopharmaceuticals is the central entity, reporting positive Phase 2 results for CBL-514 in Dercum's Disease and outlining expansion into Lipedema. The results support its pipeline value and future partnership potential, though its shares traded modestly lower after the announcement.
Sep 23, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Caliway Biopharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.